Anthrax News and Research RSS Feed - Anthrax News and Research

Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in wild and domestic lower vertebrates (cattle, sheep, goats, camels, antelopes, and other herbivores), but it can also occur in humans when they are exposed to infected animals or tissue from infected animals.

Anthrax is most common in agricultural regions where it occurs in animals. These include South and Central America, Southern and Eastern Europe, Asia, Africa, the Caribbean, and the Middle East. When anthrax affects humans, it is usually due to an occupational exposure to infected animals or their products. Workers who are exposed to dead animals and animal products from other countries where anthrax is more common may become infected with B. anthracis (industrial anthrax). Anthrax outbreaks occur in the United States on an annual basis in livestock and wild game animals such as deer.

Anthrax infection can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. B. anthracis spores can live in the soil for many years, and humans can become infected with anthrax by handling products from infected animals or by inhaling anthrax spores from contaminated animal products. Anthrax can also be spread by eating undercooked meat from infected animals. It is rare to find infected animals in the United States.
Guardian system can predict risk of dangerous diseases

Guardian system can predict risk of dangerous diseases

If an infectious disease outbreak or an attack using an agent such as anthrax were to occur in Chicago, it most likely first will be noticed in emergency rooms throughout the city. Swift identification of the cause of an incoming patients' illness could be crucial to public health and safety personnel being able to intervene in time to save lives. [More]
Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

On Friday, March 18, the U.S. Food and Drug Administration approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs. Anthim is also approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate. [More]
Discoveries could lead to development of novel therapies to prevent C. diff infection

Discoveries could lead to development of novel therapies to prevent C. diff infection

Researchers at Vanderbilt University Medical Center have obtained the crystal structure of a toxin from the bacterium Clostridium difficile ("C. diff") -- the leading cause of hospital-acquired diarrhea in the United States. [More]
PharmAthene to be compensated for loss of profits over SIGA's smallpox antiviral drug

PharmAthene to be compensated for loss of profits over SIGA's smallpox antiviral drug

PharmAthene, Inc. announced today that the Delaware Supreme Court affirmed the Delaware Court of Chancery's decision to award PharmAthene lump sum expectation damages for the value of PharmAthene's lost profits for SIGA's smallpox antiviral, Tecovirimat. [More]
Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive results in its Phase 2 clinical trial, in which SGX942, a first-in-class Innate Defense Regulator (IDR), at a dose of 1.5 mg/kg, successfully reduced the median duration of severe oral mucositis by 50% in all patients and by 67% in patients receiving the most aggressive chemoradiation therapy (CRT) for treatment of their head and neck cancer. [More]
Rutgers scientists uncover biological pathways that provide insight into tiny cell bubbles

Rutgers scientists uncover biological pathways that provide insight into tiny cell bubbles

Rutgers scientists have uncovered biological pathways in the roundworm that provide insight into how tiny bubbles released by cells can have beneficial health effects, like promoting tissue repair, or may play a diabolical role and carry disease signals for cancer or neurodegenerative diseases like Alzheimer's. [More]
Containing airborne contaminants: an interview with Gary Broomhead, Cantel Medical

Containing airborne contaminants: an interview with Gary Broomhead, Cantel Medical

There are two types of protection, sample protection keeps the sample away from contaminants in the air; and operator protection, which protects the scientist from harm from whatever they’re working on [More]
BioThrax approved to prevent disease after exposure to anthrax spores

BioThrax approved to prevent disease after exposure to anthrax spores

The U.S. Food and Drug Administration today approved a new indication for BioThrax (Anthrax Vaccine Adsorbed) to prevent disease following suspected or confirmed exposure to Bacillus anthracis, the bacterium that causes anthrax disease. The vaccine's new use is approved for people 18 through 65 years of age in conjunction with recommended antibiotic treatment. BioThrax was initially approved by the FDA in 1970 for the prevention of anthrax disease in persons at high risk of exposure. [More]
TGen receives 2015 Regents' Award for Outstanding Service to Higher Education

TGen receives 2015 Regents' Award for Outstanding Service to Higher Education

The Arizona Board of Regents presented the Translational Genomics Research Institute with its 2015 Regents' Award for Outstanding Service to Higher Education, recognizing the extensive research TGen has conducted in association with Northern Arizona University. [More]
Generex agrees to acquire 51% equity interest in Hema Diagnostic Systems

Generex agrees to acquire 51% equity interest in Hema Diagnostic Systems

Generex Biotechnology Corporation today announced that it has entered into a non-binding Letter of Intent (LOI) with Hema Diagnostic Systems, LLC (HDS), a Florida company that designs and manufactures proprietary infectious disease detection technologies. [More]
Glide Technologies, Cilian collaborate to develop solid dose formulation of recombinant influenza vaccine

Glide Technologies, Cilian collaborate to develop solid dose formulation of recombinant influenza vaccine

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines, today announced that it has entered a collaboration with German biotechnology company Cilian AG to develop a solid dose formulation of Cilian's experimental recombinant influenza vaccine, CiFlu, for delivery using Glide's patient-friendly SDI delivery device. [More]
Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has completed enrollment of the additional subjects, as directed by the Data Review Committee (DRC) earlier this year, into the company's Phase 2 study for SGX942. [More]
Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP). [More]
NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance the development of Soligenix's heat stabilized ricin toxin vaccine, RiVax. [More]
European Commission grants orphan drug designation to SGX301 for treatment of CTCL

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system. [More]
Soligenix signs $10M equity purchase agreement with accredited institutional investors

Soligenix signs $10M equity purchase agreement with accredited institutional investors

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has entered into a $10 million equity purchase agreement with accredited institutional investors, Kodiak Capital Group, LLC, Kingsbrook Opportunities Master Fund LP and River North Equity, LLC. [More]
Elusys’ Anthim BLA to treat inhalational anthrax accepted for review by the FDA

Elusys’ Anthim BLA to treat inhalational anthrax accepted for review by the FDA

Elusys Therapeutics, Inc. today announced the U.S. Food and Drug Administration has accepted for filing and review its Biologics License Application for Anthim® (obiltoxaximab) for the treatment and prevention of inhalational anthrax, a top bioterror threat which was submitted on March 20, 2015. Anthim is a candidate for future acquisition into the Strategic National Stockpile, the U.S. government's repository of critical medical supplies for biowarfare preparedness. [More]
UVA scientists find blueprint for combating human disease using DNA clad in near-indestructible armor

UVA scientists find blueprint for combating human disease using DNA clad in near-indestructible armor

By unlocking the secrets of a bizarre virus that survives in nearly boiling acid, scientists at the University of Virginia School of Medicine have found a blueprint for battling human disease using DNA clad in near-indestructible armor. [More]
Soligenix, Emergent BioSolutions sign development agreement

Soligenix, Emergent BioSolutions sign development agreement

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has initiated a development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for the RiVax drug substance protein antigen. [More]
Sandia biosciences technologies could soon find their way into doctors' offices

Sandia biosciences technologies could soon find their way into doctors' offices

Technologies developed in Sandia National Laboratories' biosciences program could soon find their way into doctors' offices -- devices like wearable microneedles that continuously analyze electrolyte levels and a lab-on-a-disk that can test a drop of blood for 64 different diseases in minutes. [More]
Advertisement